摘要
目的探讨环氧合酶-2抑制剂美洛昔康联合顺铂治疗卵巢癌的临床效果。方法选取2012年6月至2013年6月间山东省临朐县人民医院收治的90例卵巢癌患者,采用随机数字表法分为观察组与对照组,每组45例。观察组患者给予顺铂+美洛昔康治疗,对照组患者给予顺铂+紫杉醇治疗,对比两组患者临床疗效、随访3年复发情况及生存率。结果观察组患者总有效率为84.4%,对照组患者为64.4%,两组比较,差异有统计学意义(P<0.05)。观察组患者随访3年内存在影像学进展复发者、血清CA125升高者、影像学及血清CA125均异常者、腹胀腹痛等不适感者和生存率分别为8.9%、13.3%、6.7%、13.3%和86.7%,对照组患者分别为17.8%、22.2%、15.6%、24.4%和66.7%,两组比较,差异均有统计学意义(均P<0.05)。结论环氧合酶-2抑制剂美洛昔康联合顺铂治疗卵巢癌临床效果显著,延缓了肿瘤进展,避免了复发。
Objective To examine the efficacy of cyclooxygenase 2 inhibitor meloxicam combined with cisplatin in the treatment of ovarian cancer. Methods From June 2012 to June 2013,90 patients with ovarian cancer treated at People＇s Hospital of Linqu County were selected. Using random number table method,these patients were divided into an observation group and a control group with 45 patients in each group. Patients in the observation group were given cisplatin plus meloxicam and patients in the control group were given cisplatin plus paclitaxel. Clinical efficacy and recurrence and survival at follow up of 3 years were compared between the two groups. Results The overall efficacy rate was 84. 4 %for the observation group and 64. 4 % for the control group（ P 0. 05）. Proportion of evidence based recurrence of imaging progression,increased serum CA125,abnormal imaging and serum 125,abdominal pain and discomfort and survival rate during the 3-year follow-up period was 8. 9%,13. 3%,6. 7%,13. 3% and 86. 7% respectively for the observation group and 17. 8%,22. 2%,15. 6%,22. 2% and66. 7% for the control group（ P 0. 05）. Conclusion Cyclooxygenase 2 inhibitor meloxicam combined with cisplatin has a good efficacy in the treatment of ovarian cancer,which can delay the progression of neoplasms and avoid recurrence.
作者
李瑞玉
张香兰
吕君荣
LI Rui-yu ZHANG Xiang-lan LYU Jun-rong(Department of Gynaecology, People＇s Hospital of Linqu County,Weifang 262600,Chin)
出处
《中国肿瘤临床与康复》
2017年第2期182-184,共3页
Chinese Journal of Clinical Oncology and Rehabilitation
